News

The Phase I study was commenced during the first quarter of 2010 to evaluate the safety, tolerability and pharmacokinetic profile of QPI-1007 in patients with chronic nerve atrophy

Agensys and Seattle Genetics said that the study is designed to recruit up to 60 patients at multiple centers in the US. ASG-5ME is an antibody-drug conjugate (ADC)

Under the contract, Pfizer will make an upfront payment of $240m and Teuto will be eligible to receive a performance-based milestone payment. Pfizer has an option to acquire

The Classic I study was a randomised, double-blind, placebo-controlled clinical trial that compared Clolar in combination with cytarabine to cytarabine plus placebo in patients 55 years and older

Novartis posted a net income of $2.31bn for the third quarter 2010, compared to $2.11bn for the comparable period in 2009. The operating loss was $2.59bn, compared to

The software integration supports academic and commercial researchers studying genes affects and individuals response to drug treatments. According to the companies, joint customers will have a clear workflow

Under the non-binding LOI, the parties will contribute technology, research and development and other resources and will negotiate the formation of a joint venture, for the development and

Genzyme has posted a net income of $68.95m for the third quarter 2010, or $0.26 per diluted share, compared to $16m, or $0.06 per diluted share, for the

Teplizumab, also called MGA031 and hOKT31 (Ala-Ala), is a humanized, anti-CD3 monoclonal antibody. It is an investigational biologic under development for the treatment of individuals with recent-onset type